ANI Pharmaceuticals Inc expected to post earnings of 86 cents a share - Earnings Preview

ANI Pharmaceuticals

27/02/2024 14:30

* ANI Pharmaceuticals Inc  ANIP.OQ   ANIP.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
29 for the period ending December 31 2023
    * The Baudette Minnesota-based  company is expected to
report a
29.7% increase in revenue to $122.207 million from $94.23
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for ANI Pharmaceuticals Inc
is for
earnings of 86 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ANI
Pharmaceuticals Inc is $71.00​, above​ its last closing price
of $60.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.85        0.84       1.27      Beat    50.6
 Jun. 30 2023  0.67        0.68       1.28      Beat    88.9
 Mar. 31 2023  0.36        0.35       1.17      Beat    231.9​
 Dec. 31 2022  0.66        0.67       0.76      Beat    13.1
 ​​Sep.        0.55        0.55       0.64      Beat    15.8
 30 2022                                                
 Jun. 30 2022  0.22        0.22       0.13      Missed  -40.9​
 Mar. 31 2022  0.10        0.09       -0.12     Missed  -228.6
 Dec. 31 2021  0.82        0.74       0.54      Missed  -27
 This summary was machine generated February 27 at 14:30 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)